LBIO (Longevity Biomedical) Probability of Financial Distress (%)

Longevity Biomedical  (NAS:LBIO) Probability of Financial Distress (%) Explanation

Like the Altman Z-Score, the PFD measures a company's bankruptcy risk in the upcoming year. However, the main drawback of the Z-score is it does not apply to banks and insurance companies. According to Investopedia, the concept of "working capital" does not apply to banks and insurance companies, as financial institutions do not have typical current assets or current liabilities like inventories or accounts payable.

Longevity Biomedical Probability of Financial Distress (%) Related Terms

The historical data trend for Longevity Biomedical's Probability of Financial Distress (%) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Longevity Biomedical Probability of Financial Distress (%) Chart

LBIO vs : Probability of Financial Distress (%) Comparison

For the Biotechnology subindustry, Longevity Biomedical's Probability of Financial Distress (%), along with its competitors' market caps and Probability of Financial Distress (%) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Longevity Biomedical Probability of Financial Distress (%) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Longevity Biomedical's Probability of Financial Distress (%) distribution charts can be found below:

* The bar in red indicates where Longevity Biomedical's Probability of Financial Distress (%) falls into.

Longevity Biomedical Business Description